Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss.

Weight trajectories differed significantly among patients with HIV during the first year of ART, with no associations observed between weight gain and type of ART regimen.

Amid the soaring use of glucagon-like peptide-1 (GLP-1) drugs for intentional weight loss, a vastly different movement appears to be gaining traction in health care: Many clinicians are pushing for a ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Researchers linked higher weight loss after initiating antiobesity meds to lower risk for revision of hip and knee replacement.

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. The scenarios in ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The researchers found that the 5-year risks for revision among 3691 participants was 5.6% for patients in the weight gain or stable weight group compared with 3.9% in patient with greater than 10% ...

structured approach to weight loss and metabolic health,” explains Serena Poon, C.N., CHC, CHN, certified nutritionist, celebrity chef, and wellness and longevity advisor. Meet the experts ...

Here's what to know about how mushroom coffee could affect your metabolism. The post Does mushroom coffee help you lose ...

The future of American drug innovation is threatened by U.S. regulations that permit knockoff versions of new drugs to be ...

Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...